Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1991-11-20
pubmed:abstractText
The production of beta-lactamase is the most important mechanism of bacterial resistance to beta-lactam antibiotics. Attempts to find an inhibitor of beta-lactamase were made as early as the 1940s and 1950s but without success. In the early 1950s, it was found that certain semisynthetic penicillins could function as beta-lactamase inhibitors, but none found a clinical place in this capacity. A program of screening microorganisms for the production of naturally occurring inhibitors was begun in 1967. This process led to the discovery of the olivanic acids and clavulanic acid. Clavulanic acid, formulated with amoxicillin and later with ticarcillin, became available for clinical use in 1981. Since the introduction of clavulanic acid, other beta-lactamase inhibitors have been developed, including sulbactam and tazobactam. It remains to be seen whether these will have any advantage over clavulanate for clinical use.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0162-0886
pubmed:author
pubmed:issnType
Print
pubmed:volume
13 Suppl 9
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S727-32
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:articleTitle
Evolution of beta-lactamase inhibitors.
pubmed:affiliation
Chemotherapeutic Research Centre, Brockham Park, Betchworth, Surrey, United Kingdom.
pubmed:publicationType
Journal Article, Review